We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

85 hedge funds and large institutions have $429M invested in Crinetics Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

20% more funds holding

Funds holding: 71 → 85 (+14)

0.16% more ownership

Funds ownership: 92.26% → 92.42% (+0.16%)

10% less capital invested

Capital invested by funds: $475M → $429M (-$46.5M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
85
Holders Change
+14
Holders Change %
+19.72%
% of All Funds
1.5%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
20
Increased
33
Reduced
15
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.93M
2
DCM
Driehaus Capital Management
Illinois
+$8.07M
3
BlackRock
BlackRock
New York
+$4.38M
4
BBA
Baker Bros. Advisors
New York
+$4.38M
5
Morgan Stanley
Morgan Stanley
New York
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$24.6M
2
EAM
Eventide Asset Management
Massachusetts
-$13.2M
3
OM
Opaleye Management
Massachusetts
-$3.76M
4
IC
Ikarian Capital
Texas
-$784K
5
N
Nuveen
North Carolina
-$592K
Name Holding Trade Value Shares
Change 		Change in
Stake
SMH
51
Sanders Morris Harris
Texas
$263K – – –
CS
52
Credit Suisse
Switzerland
$261K +$257K +18,470 New
HSBC Holdings
53
HSBC Holdings
United Kingdom
$252K +$24.9K +1,791 +11%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$243K +$11.6K +830 +5%
Squarepoint
55
Squarepoint
New York
$217K +$215K +15,406 New
Millennium Management
56
Millennium Management
New York
$205K +$202K +14,538 New
UBS AM
57
UBS AM
Illinois
$205K +$55.7K +4,000 +38%
MIM
58
MetLife Investment Management
New Jersey
$180K – – –
VOYA Investment Management
59
VOYA Investment Management
Georgia
$177K +$174K +12,512 New
OQS
60
Occudo Quantitative Strategies
Florida
$158K +$156K +11,230 New
ProShare Advisors
61
ProShare Advisors
Maryland
$156K +$154K +11,075 New
Barclays
62
Barclays
United Kingdom
$153K -$46.4K -3,333 -23%
Citigroup
63
Citigroup
New York
$145K +$73.2K +5,254 +105%
Russell Investments Group
64
Russell Investments Group
United Kingdom
$140K +$122K +8,782 +732%
DekaBank Deutsche Girozentrale
65
DekaBank Deutsche Girozentrale
Germany
$129K +$139K +10,000 New
MLICM
66
Metropolitan Life Insurance Company (MetLife)
New York
$124K – – –
BNP Paribas Financial Markets
67
BNP Paribas Financial Markets
France
$90.5K -$2.27K -163 -2%
TRCT
68
Tower Research Capital (TRC)
New York
$86K -$234K -16,811 -73%
Bank of Montreal
69
Bank of Montreal
Ontario, Canada
$60K +$40.5K +2,907 +232%
Legal & General Group
70
Legal & General Group
United Kingdom
$57K – – –
WC
71
Wexford Capital
Florida
$43K +$42.9K +3,080 New
AIP
72
Ameritas Investment Partners
Nebraska
$34K – – –
Canada Life
73
Canada Life
Manitoba, Canada
$32K – – –
UBS Group
74
UBS Group
Switzerland
$30K +$29.2K +2,099 New
JCM
75
Jacobi Capital Management
Pennsylvania
$21K -$20.9K -1,500 -50%
1 2
3
4

CRNX Hedge Fund Activity: Q4 2020 in Review

85 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2020, worth a combined $429M — down 9.8% from $475M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CRNX positions and 6 closed out — a net gain of 14 holders — while 33 added to existing stakes and 15 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $9.93M. The largest seller was RA Capital Management, cutting an estimated $24.6M.

  • 85 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2020, up from 71 in Q3 2020.
  • Funds reported $429M of Crinetics Pharmaceuticals stock for Q4 2020, down 9.8% quarter-over-quarter.
  • 20 funds opened new Crinetics Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +14 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q4 2020 was Point72 Asset Management, an estimated $9.93M added.
  • The largest Crinetics Pharmaceuticals seller in Q4 2020 was RA Capital Management, an estimated $24.6M sold.

Based on aggregated 13F filings for Q4 2020.